WHAT'S HAPPENING IN MY REGION?

Selected region : east
Date: : 26th Jun 2019

For All Current Studies ongoing in the East click HERE.

SHARE Studies

UKRI Childcare and Wellbeing in Times of Covid-19: Developing crisis-resilient care solutions

The closure of schools and childcare services in the wake of Covid-19 has created a national ‘childcare crisis’ with potentially severe effects on families’ livelihoods and wellbeing, particularly for families in vulnerable circumstances. Since Covid-19 and its impacts are likely to be persistent, there is an urgent need for crisis-resilient childcare solutions for all families beyond key workers. This study explores the experiences of families with childcare challenges during lockdown and other social distancing measures.

For more information about this study please click here.

CORONAGENES
Researchers at the University of Edinburgh aim to understand the genetic susceptibility to coronavirus infection. They will also examine the genetic influences on the severity and outcomes of coronavirus, particularly for less severe cases. The focus will not just be individuals who are admitted to hospital and critical care.

They are looking for both participants who are suffered from COVID-19 and those who have not. People who have not contracted the disease or had symptoms are just as important to the study as people who have.

For more information about this study please click here.

ELVIS-COVID

The University of Edinburgh are running a study called ELVIS COVID-19 to find out if nasal washout and gargling with salt water helps individuals with COVID-19 get better faster by helping to ease the symptoms of the virus.

If you have developed symptoms of COVID-19 including a continuous cough or high temperature or loss of sense of smell or taste within the past 48 hours, the study team would appreciate your help with this study.

For more information about this study please click here.

 

Other studies ongoing in the East of Scotland 

For All Current Studies ongoing in the East click HERE.

Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.

The purpose of the study is to evaluate how safe, how effective and how well tolerated, the study drug Olokizumab is, in the long-term, in patients with Rheumatoid Arthritis (RA) who have previously taken part in and completed 24 weeks of blinded treatment in one of the core studies - CREDO 1, 2 or 3.

PROFILE - personalised medicine in Crohn's disease

Crohn’s disease is a type of inflammatory bowel disease (IBD) that can affect any part of the intestine. The severity of Crohn’s disease varies a lot between different people, and this means that what might be the best treatment for one person may not be appropriate for someone else. This study will see whether a simple blood test (‘biomarker’) can improve Crohn’s disease outcomes and reduce the number of flares experienced by enabling delivery of ‘personalised therapy’ (that is, treatment tailored to the individual person based on their predicted disease course and severity).

Lowering Events in Non-proliferative retinopathy in Scotland

The aim of this study is to evaluate if fenofibrate therapy will slow the progression of diabetic retinopathy.

Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

The Precision-Panc Master Protocol is a "portal" protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Studies) examining different treatment regimens and/or biomarker development.

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

The primary objective of Enroll-HD is to develop a comprehensive repository of prospective and systematically collected clinical research data (demography, clinical features, family history, genetic characteristics) and biological specimens (blood) from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g., spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation).

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

Appropriate Dosing to Optimise Personalised Cancer Treatments

This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted treatment with BRAF and MEK inhibitors.

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or durvalumab in HER2-positive advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma patients. 
Open to: All Genders

Age: 18 Years - 130 Years

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients.

This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA (salbutamol) or anti inflammatory reliever (SYMBICORT®) as reliever medication in addition to SYMBICORT as daily asthma controller.

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before